An interventional study of Non-invasive stress test and Medical treatment without further testing in Coronary Atherosclerosis Due to Calcified Coronary Lesion, sponsored by Samsung Medical Center. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-01-14.
Sponsored by Samsung Medical Center · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Coronary Artery Disease by Samsung Medical Center — 10 open to participants now, 14 under way, none of them phase 3. Coronary Artery Disease · Samsung Medical Center.
Among the 31 studies in Coronary Artery Disease by Samsung Medical Center, this one is the 3rd largest by planned enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2023, is one of 16 with no phase, reaches primary completion later than 9 of the 13 other live ones, and was the 20th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →10 of the 31 studies in Coronary Artery Disease by Samsung Medical Center are open now, in 1 country. Recruiting first, the newest first:
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
Samsung Medical Center · Sites in Korea, Republic of
Ages 18+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,000 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 520 across the 21 interventional studies, 16,487 across the 10 observational. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Samsung Medical Center is the lead sponsor of 1,013 studies on the registry; 153 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.
3 of the studies in Coronary Artery Disease by Samsung Medical Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03169985Samsung Medical CenterRandomized Controlled Trial of Moderate-Intensity Rosuvastatin With Ezetimibe Combination Therapy Versus High-Intensity Rosuvastatin on Progression of Coronary Atherosclerotic Plaque | 2027-01-28 |
| NCT04014803Samsung Medical CenterAspirin and a PoTent P2Y12 Inhibitor Versus Aspirin and Clopidogrel in Patients Undergoing PCI for Complex Lesion | 2027-06-30 |
| NCT05221931Samsung Medical CenterDrug-Coated Balloon in Patients With High Bleeding Risk | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 31 studies in Coronary Artery Disease by Samsung Medical Center, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the SMART-EXAM (SMart Angioplasty Research Team-Pragmatic Randomized Trial for Comparing Routine versus As-Needed EXercise or Pharmacologic Stress Testing in Asymptomatic Patients with High-Risk Coronary CalciuM) trial is to compare the major adverse cardiovascular events between routine stress testing and as-needed stress testing in asymptomatic patients with high-risk coronary calcium (Agatston Score ≥ 400) without proven ASCVD.
The coronary artery calcium (CAC) scan, a marker of subclinical coronary atherosclerosis, has become popular for individuals at risk for atherosclerotic cardiovascular disease. CAC is strongly associated with atherosclerotic burden and predicts coronary heart disease events and mortality, regardless of their age, sex, race, or atherosclerotic cardiovascular disease (ASCVD) risk. Furthermore, the progression of CAC is associated with an increased risk for future hard and total coronary heart disease events. The use of CAC scoring was associated with significant improvements in the reclassification and discrimination of incident ASCVD. Nevertheless, the current guidelines recommend CAC measurement for selected cases only with borderline or intermediate risk of ASCVD. However, in real-world practice, CAC testing is increasingly being promoted to the public as a means of self-assessment of cardiovascular risk and is widely being used regardless of ASCVD risk.
Non-invasive stress testing is often recommended to exclude potentially dangerous coronary artery disease. However, stress testing in asymptomatic individuals has low sensitivity and specificity.9 Although the 2019 Primary Prevention of Cardiovascular Disease Guidelines do not comment on functional or invasive testing in asymptomatic individuals with a high CAC score, the 2009 Appropriate Use Criteria for Cardiac Radionuclide Imaging report gives a level A recommendation for obtaining a stress test in asymptomatic individuals with CAC score ≥400.10 In addition, the 2013 update of the 2009 document also considers stress imaging appropriate for patients with CAC score >100. However, there have been no large randomized controlled trials or observational studies that have evaluated the utility of functional or invasive testing in asymptomatic individuals free of ASCVD with high CAC scores. Theoretically, early detection and revascularization of ischemia producing lesions in asymptomatic patients with high-risk coronary calcification without proven ASCVD might reduce the future risk of major adverse cardiovascular events.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Documentation of objective evidence of inducible ischemia before enrollment
Presence of significant coronary artery stenosis (≥ 70% diameter stenosis) confirmed by coronary angiography or coronary computed tomography angiography before enrollment
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In this group, the preselected functional stress testing (exercise electrocardiography, stress echocardiography, nuclear imaging, or stress cardiac magnetic resonance imaging) will be performed within three months (± 2 months) according to the practice pattern of each participating center.
Diagnostic Test: Non-invasive stress test
In this group, optimal medical treatment will be performed by current guidelines without further testing. A stress test will be performed only when new symptoms (exertional chest pain or dyspnea) occur that may clinically suggest significant coronary artery disease.
Diagnostic Test: Medical treatment without further testing
Nuclear imaging, stress echocardiography, exercise electrocardiography, stress cardiac magnetic resonance imaging
Optimal medical treatment for primary prevention.
Occurrence of major adverse cardiovascular events
a composite of death from cardiovascular causes, myocardial infarction, unplanned hospitalization leading to an urgent revascularization procedure, or heart failure hospitalization
Time frame: up to 4.5 years of median follow-up
cardiovascular death
death from cardiovascular causes
Time frame: up to 4.5 years of median follow-up
myocardial infarction
myocardial infarction
Time frame: up to 4.5 years of median follow-up
unplanned hospitalization leading to an urgent revascularization procedure
unplanned hospitalization leading to an urgent revascularization procedure
Time frame: up to 4.5 years of median follow-up
heart failure hospitalization
heart failure hospitalization
Time frame: up to 4.5 years of median follow-up
all-cause death
death from any causes
Time frame: up to 4.5 years of median follow-up
a composite of death from cardiovascular cause or myocardial infarction
a composite of death from cardiovascular cause or myocardial infarction
Time frame: up to 4.5 years of median follow-up
any hospitalization
any hospitalization
Time frame: up to 4.5 years of median follow-up
performing revascularization procedure
performing revascularization procedure
Time frame: up to 4.5 years of median follow-up
performing invasive coronary angiography procedure
performing invasive coronary angiography procedure
Time frame: up to 4.5 years of median follow-up
stroke
stroke
Time frame: up to 4.5 years of median follow-up
bleeding
Bleeding Academic Research Consortium type 2-5
Time frame: up to 4.5 years of median follow-up
total medical cost
total medical cost
Time frame: up to 4.5 years of median follow-up
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jul 2023 (actual). Primary completion is estimated for Jun 2029, 71 months after the start.
Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 71 months is above that.
Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.